So, it is going to get better. It is going to get faster. Members are--house calls, right?

When is that going to happen?

we are very concerned that we continue to make sure in the rural part of our country--where about 40 percent of our population lives, roughly--have access to the health care they have earned and they so deserve.

Thank you all very much for being here and being a service to our country. We very much appreciate it.

There are plans for a House companion bill to S. 1611 to be introduced in the near future by Representative Bruce Poliquin.

My mind is racing, but I think prudence dictates no response.

There have to be consequences, otherwise everybody is going to come after us, not just Russia, but North Korea, Iran, and terrorist organizations.

Right now, we are not imposing much in the way of consequences.

If all we do is try to patch networks and defend ourselves, we will ultimately lose.

I want to just associate myself with the comments and questions that were made by Senator Inhofe and I think Senator Shaheen about open source software and some of the policy discussions we are having here.

I think you fellows understated one important point, and I do not understand why the representative from the White House is not here because I think he has a reasonable story to tell.

Part of the problem also is we tend to want to keep secret what we can do when, in reality, a secret deterrent is not a deterrent.

I want to emphasize the importance of that, because if you look back over the past 50 years, many of our foreign policy disasters were based upon skewed intelligence, based upon the desires of the policymakers, whether it was the Bay of…

you need an IG to look at this and shine that flashlight, shine that light on those activities

We looked at Turing, we looked at Valeant, and what we found was a pattern of certain, what I call, hedge fund pharma companies buying the rights to a drug and then, overnight, increasing the cost by as much as literally 5,000 percent in…

There wasn't any investment in R and D that would justify that kind of increase.

One of the issues that really troubles me is the lack of transparency in the system.

Last year, the Senate Aging Committee did an extensive investigation into the spiraling cost increases of certain prescription drugs.